免疫磁珠分选肾癌干细胞及端粒酶活性在肾癌干细胞中的表达  

Telomerase activity in RCC stem cells sorted by magnetic activated cell sorting system

作　　者：孙浩[1] 田福起[1] 郭涛[1] 潘鹏[1] 姚宏伟[1] 何鸿保[1] 

机构地区：[1]江苏大学附属医院泌尿外科,镇江212001

出　　处：《江苏医药》2010年第12期1414-1417,共4页Jiangsu Medical Journal

基　　金：镇江市科技局资助项目(SH2007024)

摘　　要：目的探讨肾癌干细胞端粒酶活性的改变。方法利用无血清悬浮培养的方法培养富集肾癌干细胞,流式细胞分析技术检测其CD133的表达,用免疫磁珠分选系统分离CD133+及CD133-细胞,以正常肾组织细胞作为阴性对照,采用TRAP实时定量的方法分别检测肾癌CD133+及CD133-细胞端粒酶活性。结果 CD133+细胞和CD133-端粒酶活性分别为(20.54±2.45)和(20.69±2.53)Ct值,而正常肾组织没有检测出端粒酶活性(P<0.05)。结论肾癌干细胞端粒酶活性明显增高。Objective To detect telomerase activity in renal carcinoma stem cells.MethodsThe method of suspension culture in serum free medium was used to enrich renal cell carcinoma（RCC） stem cells,in which the expression of CD133 was detected by flow cytometry.CD133^＋ and CD133^-cells were separated with magnetic activated cell sorting system.Then real-time quantitative TRAP assay was applied to evaluate the telomerase activity in CD133^＋ and CD133^-cells.The normal renal cells were taken as the negative controls.Results Telomerase activity in CD133^＋ and CD133^-cells were （20.54±2.45） and （20.69±2.53） Ct,respectively.There was no telomerase activity seen in the normal somatocytes.Conclusion The telomerase activity in RCC stem cells is remarkably increased.

关 键 词：肿瘤干细胞 肾癌 端粒酶 CD133 

分 类 号：R737[医药卫生—肿瘤]